Literature DB >> 18318772

HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation.

Christian Britschgi1, Mathias Jenal, Mattia Rizzi, Beatrice U Mueller, Bruce E Torbett, Anne-Catherine Andres, Andreas Tobler, Martin F Fey, Mario P Tschan.   

Abstract

A hallmark of acute myeloid leukaemia (AML) is a block in differentiation caused by deregulated gene expression. The tumour suppressor Hypermethylated In Cancer 1 (HIC1) is a transcriptional repressor, which is epigenetically silenced in solid cancers. HIC1 mRNA expression was found to be low in 128 patient samples of AML and CD34+ progenitor cells when compared with terminally differentiated granulocytes. HIC1 mRNA was induced in a patient with t(15;17)-positive acute promyelocytic leukaemia receiving all-trans retinoic acid (ATRA) therapy. We therefore investigated whether HIC1 plays a role in granulocytic differentiation and whether loss of function of this gene might contribute to the differentiation block in AML. We evaluated HIC1 mRNA levels in HL-60 and U-937 cells upon ATRA-induced differentiation and in CD34+ progenitor cells after granulocyte colony-stimulating factor-induced differentiation. In both models of granulocytic differentiation, we observed significant HIC1 induction. When HIC1 mRNA was suppressed in HL-60 cells using stably expressed short hairpin RNA targeting HIC1, granulocytic differentiation was altered as assessed by CD11b expression. Bisulphite sequencing of GC-rich regions (CpG islands) in the HIC1 promoter provided evidence that the observed suppression in HL-60 cells was not because of promoter hypermethylation. Our findings indicate a role for the tumour suppressor gene HIC1 in granulocytic differentiation. Low expression of HIC1 may very well contribute to pathogenic events in leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318772     DOI: 10.1111/j.1365-2141.2008.06992.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

Review 1.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

2.  Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with nonsmall cell lung carcinoma: a case report.

Authors:  Sulhattin Arslan; Tamer Dogan; Binnur Koksal; Malik Ejder Yildirim; Cesur Gumus; Sahenda Elagoz; Ibrahim Akkurt; Oztürk Ozdemir
Journal:  Lung India       Date:  2008-10

3.  Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma.

Authors:  Heike Stöcklein; Grit Hutter; Jörg Kalla; Elena Hartmann; Yvonne Zimmermann; Tiemo Katzenberger; Patrick Adam; Ellen Leich; Sylvia Höller; Hans Konrad Müller-Hermelink; Andreas Rosenwald; German Ott; Martin Dreyling
Journal:  J Hematop       Date:  2008-07-05       Impact factor: 0.196

4.  p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.

Authors:  A Trocoli; P Bensadoun; E Richard; G Labrunie; F Merhi; A M Schläfli; D Brigger; S Souquere; G Pierron; J-M Pasquet; P Soubeyran; J Reiffers; E Ségal-Bendirdjian; M P Tschan; M Djavaheri-Mergny
Journal:  Cell Death Differ       Date:  2014-07-18       Impact factor: 15.828

5.  Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1).

Authors:  Capucine Van Rechem; Brian R Rood; Majid Touka; Sébastien Pinte; Mathias Jenal; Cateline Guérardel; Keri Ramsey; Didier Monté; Agnès Bégue; Mario P Tschan; Dietrich A Stephan; Dominique Leprince
Journal:  J Biol Chem       Date:  2009-06-12       Impact factor: 5.157

6.  Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.

Authors:  Yan-Fang Tao; Shao-Yan Hu; Jun Lu; Lan Cao; Wen-Li Zhao; Pei-Fang Xiao; Li-Xiao Xu; Zhi-Heng Li; Na-Na Wang; Xiao-Juan Du; Li-Chao Sun; He Zhao; Fang Fang; Guang-Hao Su; Yan-Hong Li; Yi-Ping Li; Yun-Yun Xu; Jian Ni; Jian Wang; Xing Feng; Jian Pan
Journal:  Int J Mol Med       Date:  2014-10-13       Impact factor: 4.101

7.  miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.

Authors:  S Haemmig; U Baumgartner; A Glück; S Zbinden; M P Tschan; A Kappeler; L Mariani; I Vajtai; E Vassella
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

Review 8.  Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Authors:  Miao Zhang; Jia-Yi Zhang; Ming-Qian Sun; Peng Lu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2020-05-16       Impact factor: 1.978

9.  BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation.

Authors:  Anna M Schläfli; Bruce E Torbett; Martin F Fey; Mario P Tschan
Journal:  Exp Hematol Oncol       Date:  2012-09-04

10.  A PU.1 suppressive target gene, metallothionein 1G, inhibits retinoic acid-induced NB4 cell differentiation.

Authors:  Naomi Hirako; Hiroko Nakano; Shinichiro Takahashi
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.